Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei,Koji Sasaki,Joseph D Khoury,Issa F Khouri,Jovitta Jacob,Meagan Rostykus,Bouthaina S Dabaja,Patrice Nasnas,Tapan M Kadia,Nitin Jain,Marina Konopleva,Farhad Ravandi,Hagop M Kantarjian,Partow Kebriaei,Monica Kwari,Rebecca Garris,Xuelin Huang,Caitlin R Rausch,C Cameron Yin,Koichi Takahashi,Courtney D Dinardo,Jeffrey L Jorgensen,William G Wierda,Rita Khouri,Srđan Verstovšek ,Musa Yılmaz ,Paul Stolzmann ,Guillermo Garcia‐Manero ,Guillermo Montalban‐Bravo ,Nicholas J Short ,Sa A Wang ,Susan O’brien

doi:10.1182/blood-2020-143401

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, Koji Sasaki + Show 30 more

Open Access

https://doi.org/10.1182/blood-2020-143401

Copy DOI

Journal: Blood

Publication Date: Nov 5, 2020

Affiliation: The University of Texas MD Anderson Cancer Center, University of California, Irvine Medical Center

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Full Text